---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-033594"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:44:31.297186+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProKidney updates PROACT 1 enrollment target to ~470; confirmatory readout now H2 2029

## Summary
- Enrollment target increased to ~470 subjects in Phase 3 PROACT 1 (REGEN-006) study.
- Surrogate endpoint (eGFR slope) topline data readout still anticipated Q2 2027.
- Confirmatory endpoint (composite time-to-event) topline data readout now anticipated H2 2029.
- Statistical powering assumptions unchanged for both surrogate and confirmatory analyses.

## SEC filing metadata
- accession: 0001193125-26-033594
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312526033594/0001193125-26-033594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312526033594/prok-20260202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-033594
- JSON: https://secwatch.observer/filing/0001193125-26-033594.json
- Plain text: https://secwatch.observer/filing/0001193125-26-033594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.